Skip to main content

Advertisement

SpringerLink
Log in

Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed

  • Letter to the Editor
  • Published:
Hepatology International Aims and scope Submit manuscript

The Original Article was published on 01 December 2023

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The data that support the findings of our study are available from the corresponding author upon reasonable request.

References

  1. Zeng ZX, Wu JY, Wu JY, Li YN, Fu YK, Zhang ZB, et al. The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors. Hepatol Int. 2023. https://doi.org/10.1007/s12072-023-10613-x

    Article  PubMed  Google Scholar 

  2. Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy—development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–363

    Article  CAS  PubMed  Google Scholar 

  3. Zhang L, Sun T, Sun B, Zhang K, Zheng Y, Li N, et al. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor. BMC Cancer. 2024;24(1):223

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist. 2009;14(7):717–725

    Article  CAS  PubMed  Google Scholar 

  5. Wei X, Jiang Y, Zhang X, Feng S, Zhou B, Ye X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label. Multicenter Controlled Study J Clin Oncol. 2019;37(24):2141–2151

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The comment does not receive any funding.

Author information

Authors and Affiliations

  1. Department of Vascular Surgery, Nantong First People’s Hospital, The Second Affiliated Hospital of Nantong University, 666 Shengli Road, Chongchuan District, Nantong, 226014, Jiangsu, China

    Shiye Yang, Huoqi Liang, Xing Li, Jiayi Qian & Zhibing Ming

Authors
  1. Shiye Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huoqi Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiayi Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhibing Ming
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Shiye Yang: study design and writing. Zhibing Ming: critical review and study supervision.

Corresponding author

Correspondence to Zhibing Ming.

Ethics declarations

Conflict of interest

The authors who participate in this comment have no conflicts of interest to declare.

Ethical approval

Not applicable for this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, S., Liang, H., Li, X. et al. Is the TAE score a promising prognostic predictor for unresectable hepatocellular carcinoma treated with TACE plus lenvatinib with PD‑1 inhibitors? Further validation should be performed. Hepatol Int 18, 1058–1059 (2024). https://doi.org/10.1007/s12072-024-10676-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-024-10676-4

Keywords

Search

Navigation